Associated Papers
Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies.
Flümann R et al.
Blood Cancer Discovery, 2023
36346827 (PubMed )
Supplement: bcd-22-0007_table_s6_suppst6.xlsx › E_Mut_Pat.__4
Implications of CLSPN Variants in Cellular Function and Susceptibility to Cancer.
Azenha D et al.
Cancers, 2020
Benchmarking of Whole Exome Sequencing and Ad Hoc Designed Panels for Genetic Testing of Hereditary Cancer.
Feliubadaló L et al.
Scientific Reports, 2017
28050010 (PubMed )
Supplement: srep37984-s2.xls › Exome_geMODERATE_variants
The New Immortalized Uroepithelial Cell Line HBLAK Contains Defined Genetic Aberrations Typical of Early Stage Urothelial Tumors.
Hoffmann MJ et al.
Bladder Cancer (amsterdam, Netherlands), 2016
28035326 (PubMed )
Supplement: blc-2-blc160065-s001.xlsx › 2_HBLAK_relevant_SNPs
Integrative analysis of mutational and transcriptional profiles reveals driver mutations of metastatic breast cancers.
Lee JH et al.
Cell Discovery, 2016
27625789 (PubMed )
Supplement: celldisc201625-s8.pdf
Mutational analysis of thirty-two double-strand DNA break repair genes in breast and pancreatic cancers.
Wang X et al.
Cancer Research, 2008
Select a paper to view details